Title: Edaravone combined with Shuxuening injection for acute cerebral infarction:observation of clinical efficacy
Abstract: OBJECTIVE To observe the clinical efficacy and safety of edaravone combined with Shuxuening injection in the treatment of acute cerebral infarction.METHODS In a random and two-blinded way,85 patients with acute cerebral infarction within 48 h after the onset were divided into two groups:edaravone combined with Shuxuening injection group(combined group)and Shuxuening injection group(control group).For the combined group,the patients were intravenously treated with edaravone 30 mg plus N.S 250 mL,bid,and Shuxuening injection 20 mL plus 5%G lucose injection 500 mL,qd,for 14 days;while the control group was only treated with Shuxuening injection 20 mL plus 5%G lucose injection 500 mL,qd,for 14 days.Aspirin 100 mg was administrated orally to all patients simultaneously.The clinical efficacy rate and the neurological deficit scores were assessed before and two weeks after treatment.RESULTS In comparison of the combined group with the control group,the total efficacy rate of combined group was 93.02%,which was obviously better than that of control group(80.95%)(P0.01),and the neurological deficit scores significantly improved(vs control group,P0.01).No serious side-effects were observed.CONCLUSION Edaravone combined with Shuxuening injection is safe and efficient in the treatment of acute cerebral infarction.
Publication Year: 2009
Publication Date: 2009-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot